Optimizing Ublituximab Use: Real-World Experience and Future Directions

This sponsored special report has examined the evolving role of ublituximab in relapsing multiple sclerosis, with a focus on long-term outcomes from the ULTIMATE open-label extension. Across the series, expert insights have highlighted how efficacy, safety, and practical considerations are informing treatment strategies and shaping the use of B-cell–depleting therapies in clinical care.

As longer-term data continue to emerge, attention is increasingly turning toward how therapies like ublituximab are used in everyday clinical practice. In this final segment, Bruce Cree, MD, PhD, clinical research director at the UCSF Multiple Sclerosis Center, reflects on how real-world experience is informing treatment decisions, particularly in relation to infusion logistics, patient preference, and transitions from other anti-CD20 therapies.

Cree also discusses areas where additional evidence will be critical, including optimal monitoring strategies for immunoglobulin levels, management of rare safety signals, and the potential role of future formulations such as subcutaneous delivery. The conversation underscores how ongoing data collection and clinical experience will continue to refine the use of ublituximab across diverse patient populations and care settings.